Septerna (NASDAQ:SEPN) Price Target Raised to $30.00

Septerna (NASDAQ:SEPN) had its price target lifted by HC Wainwright from $26.00 to $30.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Septerna’s Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.25 EPS.

Several other equities analysts have also commented on SEPN. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Septerna in a research report on Friday, September 5th. Wall Street Zen lowered shares of Septerna from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Septerna has a consensus rating of “Moderate Buy” and a consensus price target of $27.75.

Septerna Stock Performance

Septerna stock opened at $19.24 on Tuesday. Septerna has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The stock’s 50 day simple moving average is $19.17 and its two-hundred day simple moving average is $13.65. The stock has a market cap of $861.37 million and a price-to-earnings ratio of -12.74.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $24.50 million. On average, analysts predict that Septerna will post -7.11 earnings per share for the current year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the transaction, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. The trade was a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Invesco Ltd. lifted its stake in shares of Septerna by 1,396.4% in the third quarter. Invesco Ltd. now owns 177,070 shares of the company’s stock worth $3,331,000 after buying an additional 165,237 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Septerna by 88.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after acquiring an additional 1,945 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Septerna in the 3rd quarter worth approximately $36,000. Vanguard Group Inc. lifted its position in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares in the last quarter. Finally, Covestor Ltd boosted its stake in Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after purchasing an additional 1,296 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.